Efetividade e segurança do dupilumabe na dermatite atópica
Efficacy and safety of dupilumab in atopic dermatitis
Andressa Zanandréa; Cláudia Castilho Mouco; Mara Giavina-Bianchi; Pedro Giavina-Bianchi
Resumo
Relato de caso que ilustra a eficácia e a segurança do uso do dupilumabe na dermatite atópica. O uso de anticorpos monoclonais também possibilita o maior conhecimento sobre a fisiopatogenia da doença.
Palavras-chave
Abstract
This case report shows the efficacy and safety of dupilumab in atopic dermatitis. The use of monoclonal antibodies provides further knowledge on the pathophysiology of the disease.
Keywords
Referências
1. Antunes AA, Solé D, Carvalho VO, Bau AEK, Kuschnir FC, Mallozi MC, et al. Guia prático de atualização em dermatite atópica - Parte I: etiopatogenia, clínica e diagnóstico. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria. Arq Asma Alerg Imunol. 2017;1(2):131‑56.
2. Zanandréa A, Mouco CC, Giavina-Bianchi M, Giavina-Bianchi P. Erupção variceliforme de Kaposi: subdiagnóstico. Arq Asma Alerg Imunol. 2017;1(4):431-3.
3. Giavina-Bianchi M, Giavina-Bianchi P. Systemic treatment for severe atopic dermatitis. Arch Immunol Ther Exp (Warsz). 2018;no prelo. doi: 10.1007/s00005-018-0521-y.
4. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48.
5. Xu X, Zheng Y, Zhang X, He Y, Li C. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Oncotarget. 2017;8(65):108480-91.
6. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62-9.e1.
7. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-101.
8. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-tosevere atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287‑303.
9. Giavina-Bianchi M, Giavina-Bianchi P, Rizzo LV. Dupilumabe no tratamento da dermatite atópica grave refratária a imunossupressão sistêmica: relato de caso. Einstein. 2019; no prelo.
10. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-96.
11. Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep. 2018;4(9):899-904.
12. Herz S, Petri M, Sondermann W. New alcohol flushing in a patient with atopic dermatitis under therapy with dupilumab. Dermatol Ther. 2018:e12762.
Submetido em:
31/07/2018
Aceito em:
17/12/2018
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email